Literature DB >> 9704652

Autoantibodies to DEK oncoprotein in a patient with systemic lupus erythematosus and sarcoidosis.

X Dong1, M A Michelis, J Wang, R Bose, T DeLange, W H Reeves.   

Abstract

A patient was identified with an unusual autoimmune syndrome consisting of systemic lupus erythematosus and sarcoidosis. Her serum contained extremely high levels of autoantibodies to the DEK protooncogene product. The patient's serum was used to clone a dek complementary DNA, which was expressed as a histidine-tagged fusion protein in Escherichia coli. Using affinity-purified recombinant DEK protein, anti-DEK autoantibodies were found in the patient's serum at a titer of 1:10(6) by enzyme-linked immunosorbent assay (ELISA). Longitudinal studies revealed marked variations in anti-DEK autoantibody levels over time. Although it has been suggested that anti-DEK autoantibodies are a marker for pauciarticular juvenile rheumatoid arthritis with iridocyclitis, the present data suggest that they may be associated with other disease subsets as well. The quantitative ELISA technique will be useful for defining these subsets further and for examining the relationship between anti-DEK titers and disease activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9704652     DOI: 10.1002/1529-0131(199808)41:8<1505::AID-ART23>3.0.CO;2-N

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  21 in total

1.  Protein interactions targeting the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes.

Authors:  Anita Krithivas; Masahiro Fujimuro; Magdalena Weidner; David B Young; S Diane Hayward
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Structure-specific binding of the proto-oncogene protein DEK to DNA.

Authors:  Tanja Waldmann; Martina Baack; Nicole Richter; Claudia Gruss
Journal:  Nucleic Acids Res       Date:  2003-12-01       Impact factor: 16.971

3.  Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK.

Authors:  Ferdinand Kappes; Catalina Damoc; Rolf Knippers; Michael Przybylski; Lorenzo A Pinna; Claudia Gruss
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

4.  Functional domains of the ubiquitous chromatin protein DEK.

Authors:  Ferdinand Kappes; Ingo Scholten; Nicole Richter; Claudia Gruss; Tanja Waldmann
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

5.  The DEK nuclear autoantigen is a secreted chemotactic factor.

Authors:  Nirit Mor-Vaknin; Antonello Punturieri; Kajal Sitwala; Neil Faulkner; Maureen Legendre; Michael S Khodadoust; Ferdinand Kappes; Jeffrey H Ruth; Alisa Koch; David Glass; Lilli Petruzzelli; Barbara S Adams; David M Markovitz
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

6.  Secreted nuclear protein DEK regulates hematopoiesis through CXCR2 signaling.

Authors:  Maegan L Capitano; Nirit Mor-Vaknin; Anjan K Saha; Scott Cooper; Maureen Legendre; Haihong Guo; Rafael Contreras-Galindo; Ferdinand Kappes; Maureen A Sartor; Christopher T Lee; Xinxin Huang; David M Markovitz; Hal E Broxmeyer
Journal:  J Clin Invest       Date:  2019-05-20       Impact factor: 14.808

7.  Intercellular trafficking of the nuclear oncoprotein DEK.

Authors:  Anjan K Saha; Ferdinand Kappes; Amruta Mundade; Anja Deutzmann; David M Rosmarin; Maureen Legendre; Nicolas Chatain; Zeina Al-Obaidi; Barbara S Adams; Hidde L Ploegh; Elisa Ferrando-May; Nirit Mor-Vaknin; David M Markovitz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-08       Impact factor: 11.205

8.  Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions.

Authors:  Trisha M Wise-Draper; Hillary V Allen; Elizabeth E Jones; Kristen B Habash; Hiroshi Matsuo; Susanne I Wells
Journal:  Mol Cell Biol       Date:  2006-08-07       Impact factor: 4.272

9.  The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7.

Authors:  Trisha M Wise-Draper; Hillary V Allen; Megan N Thobe; Elizabeth E Jones; Kristen B Habash; Karl Münger; Susanne I Wells
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

10.  Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.

Authors:  Dong-Mei Wang; Ling Liu; Lei Fan; Zhi-Jian Zou; Li-Na Zhang; Shu Yang; Jian-Yong Li; Wei Xu
Journal:  Cancer Biol Ther       Date:  2012-10-10       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.